苦参素治疗对慢乙肝患者TGF-β1、TNF-α、HA、PcⅢ水平的影响

目的探讨苦参素在慢性乙型肝抗肝纤维化的作用机理.方法采用ELISA和RIA方法对治疗 Ⅰ组和治疗Ⅱ组(苦参素组)治疗前及治疗6月后的慢性肝炎轻度、肝炎中度、肝炎重度及肝硬化246例患者血清转化生长因子β1(TGF-β1)、肿瘤坏死因子α(TNG-α)、透明质酸(HA)、Ⅲ型前胶原(PaⅢ)含量进行测定,并设立35例健康献血人员作为正常组.结果治疗前两组患者血清TGF-β1、TNF-α、HA、PcⅢ均不同程度的升高,与正常组相比差异显著(P＜0.05或P＜0.01);治疗后均有不同程度的降低,治疗Ⅱ组治疗后与治疗前相比明显下降(P＜0.05或P＜0.01),并与治疗Ⅰ组在慢性肝炎中度、肝炎重度、肝硬化间差异显著(P＜0.05或P＜0.01).结论苦参具有逆转肝纤维的作用,有部分机制通过抑制TGF-β1、TNF-α的分泌,并且具有良好的耐受性.

Effect of matrine on levels of TGF-β1,TNF-α,HA and Pc Ⅲ in sera of chronic hepatitis B patients

Objective:To investigate the mechanism of therapeutic effect of matrine on liver fibrosis in patients with chronic hepatitis B.Methods:The levels of transforming growth facObjective:Tor-β1(TGF-β1),tumor necrosis facObjective:Torα(TNF-α),hyaline acid(HA)and type Ⅲ procollagen(Pc Ⅲ)were detected in 246 patients with chronic mild,moderate,severe hepatitis B and liver cirrhosis in group Ⅰ and group Ⅱ(matrine group)before treatment and three months after treatment by ELISA and RIA,and 35 healthy donors served as normal group.Results:The serum levels of TGF-β1,TNF-o,HA and PcⅢ in patients with chronic hepatitis B increased notably than those of normal groups,and difference was obvious between CHB and normal group(P＜0.05 or P＜0.01).The serum levels of TGF-β1,TNF-α,HA and Pc Ⅲ decreased notably than those before treatment,after treatment with matrine.The serum levels of TGF-β1,TNF-α,HA and PcⅢ significantly decreased compared with the ones before treatment(P＜0.05 or P＜0.01),and there was significant difference in patients with chronic moderate,severe hepatitis B and liver cirrhosis between post treatment group Ⅱ and post treatment group Ⅰ(P＜0.05 or P＜0.01).Conclusions: Matrine reverses the liver fibrosis with therapeutic effect on liver fibrosis,this is partly by inhibiting secretions of TGF-β1 and TNF-α,and the patients have a good Objective:Tolerance Objective:To it.